Mitomycin-C is an antineoplastic antibiotic that acts as an alkylating agent by inhibiting DNA and protein synthesis. It can inhibit cell division, protein synthesis, and fibroblast proliferation. The purpose of this pilot study is to investigate intraoperative applications of topical mitomycin-C in treatment and prevention of glottic and subglottic stenosis. Eight patients with posterior glott...

The unpredictable clinical toxicity observed in patients treated with mitomycin C and the observation that this agent must be reduced to an active form before alkylating target molecules have led to the development of a bioassay which is capable of detecting biologically active forms of mitomycin C in the plasma of drug-treated patients. The bioassay makes use of a repair-deficient mutant of Ch...

PURPOSE Endoluminal application of mitomycin C shows promise as a nonsurgical approach to treating recalcitrant stricture but requires precise delivery to prevent mitomycin-mediated injury to adjacent normal mucosa. We describe a novel technique that uses a microporous polytetrafluoroethylene catheter balloon to endoluminally deliver mitomycin C to the target tissue while minimizing nontarget d...

Mitomycin C is an alkylating agent used in cancer chemotherapy that shows some specificity towards hypoxic cells. The therapeutic effects of this compound are thought to result from its metabolic activation by enzymes such as NADPH:cytochrome P-450 reductase. In a previous report we described a Chinese hamster ovary cell line resistant to mitomycin C, which had a decreased NADPH:cytochrome P-45...

PURPOSE To evaluate the outcome of primary or retreatment photorefractive keratectomy (PRK) or phototherapeutic keratectomy (PTK) with mitomycin C (MMC) 0.02% applied prophylactically intraoperatively for the prevention of haze and regression in cases of significant haze and regression after primary PRK, due to previous radial keratotomy (RK), in primary PRK eyes with high myopia, and in comeas...

In recent years, mitomycin C (Fig. 1) has been widely used for cancer treatment, but its clinical applications are limited owing to inherent severe toxicity. The therapeutic efficacy of mitomycin C is closely related to the drug concentration in blood and tissues, depending on the dose, route and frequency of administration. Quantitation of mitomycin C in biological fluids was first attained by...

A triple auxotroph of Bacillus megaterium strain KM was lysogenized with a phage suspension from B. megaterium 899a. The lysogenic and phage-sensitive derivatives of KM were found to die at the same exponential rate during thymineless incubation, despite the fact that the lysogenic strain became induced. The lysogenic strain was also induced by mitomycin C, and died at an exponential rate which...

The formation of chromosome aberrations induced by alkylating agents such as mitomycin C has been shown to require the passage of the treated cell through S phase. However, the exact mechanisms by which mitomycin C-induced DNA lesions are translated into chromosome aberrations during S phase are not known. The purpose of these studies was to better understand the molecular basis of chromosome a...

BACKGROUND/AIMS To investigate the in vitro effect of a short time exposure to the anthracycline idarubicin on proliferation, protein synthesis, and motility of human Tenon's capsule fibroblasts in comparison with the antitumour antibiotic mitomycin C. METHODS After determination of effective concentrations of idarubicin, fibroblasts of the human Tenon's capsule were exposed to idarubicin or ...

background: l1 retrotransposons are the most active mobile dna elements in human genome. unregulated l1 retrotransposition may have deleterious effect by disrupting vital genes and inducing genomic instabilities. therefore, human cells control l1 elements by silencing their activities through epigenetic mechanisms. it has been shown that cell division and heavy metals stimulate the frequency of...